ibandronate and Vistide Interactions

Interactions between ibandronate and Vistide (cidofovir)

cidofovir and ibandronate (Major Drug-Drug)

CONTRAINDICATED: Coadministration of cidofovir with other nephrotoxic agents may potentiate the risk of renal impairment. Dose-related nephrotoxicity is the major toxicity of cidofovir. Cases of acute renal failure resulting in dialysis and/or contributing to death have occurred with as few as one or two doses of cidofovir.

MANAGEMENT: The use of cidofovir in combination with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous bisphosphonates, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents) is considered contraindicated. Such agents should be discontinued for at least seven days prior to starting therapy with cidofovir. Initiation of cidofovir is also contraindicated in patients with a serum creatinine greater than 1.5 mg/dL, a calculated creatinine clearance at or below 55 mL/min, or a urine protein greater than or equal to 100 mg/dL.